Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects

Mohamad, Nur Afiqah; Ramachandran, Vasudevan; Mohd Isa, Hazlita; Chan, Yoke Mun; Ngah, Nor Fariza; Ching, Siew Mooi; Hoo, Fan Kee; Wan Sulaiman, Wan Aliaa; Inche Mat, Liyana Najwa; Mohamed, Mohd Hazmi

doi:10.1186/s40246-019-0197-3

Human Genomics

Table 3 Visual acuity and central retinal thickness outcome by genotype among nAMD subjects

From: Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects

		ARMS2 rs10490924 (n = 145)				HTRA1 rs11200638 (n = 145)
		GG	GT	TT	P	GG	GA	AA	P
Total (n)		21 (14.5)	57 (39.3)	67 (46.2)		19 (13.1)	47 (32.4)	79 (54.5)
Mean age (years)^a		66.47 ± 7.31	70.35 ± 7.74	68.87 ± 7.25	0.122^c	65.95 ± 7.46	69.87 ± 7.79	69.41 ± 7.26	0.137^c
Gender	Male	8 (38.1)	40 (70.2)	38 (56.7)		6 (31.6)	37 (78.7)	43 (54.4)
Gender	Female	13 (61.9)	17 (29.8)	29 (43.3)	0.032^c*	13 (68.4)	10 (21.3)	36 (45.6)	0.001^c*
Mean BCVA (logMAR) ^a	Baseline	0.59 ± 0.28	0.56 ± 0.28	0.56 ± 0.25	0.861^b	0.59 ± 0.27	0.62 ± 0.28	0.53 ± 0.25	0.190^b
	3 months	0.58 ± 0.28	0.58 ± 0.26	0.61 ± 0.27	0.771^b	0.58 ± 0.29	0.61 ± 0.27	0.59 ± 0.26	0.906^b
	6 months	0.45 ± 0.29	0.58 ± 0.28	0.62 ± 0.28	0.046^b*	0.44 ± 0.31	0.58 ± 0.27	0.61 ± 0.29	0.044^b*
Mean CRT (μM) ^a	Baseline	417.8 ± 129.82	388.7 ± 143.95	369.5 ± 134.71	0.357^c	431.5 ± 128.46	393.9 ± 151.47	366.7 ± 129.63	0.153^c
	3 months	343.9 ± 165.37	355.3 ± 131.49	353.6 ± 93.17	0.411^b	350.3 ± 172.62	357.9 ± 128.46	350.5 ± 100.83	0.665^b
	6 months	323.6 ± 144.39	339.0 ± 129.48	400.1 ± 127.90	< 0.001^b*	329.2 ± 150.19	341.7 ± 130.29	387.5 ± 129.89	0.008^b*
Changes in BCVA (logMAR) ^a	3 months	− 0.01 ± 0.21	0.02 ± 0.24	0.05 ± 0.19	0.263^b	− 0.003 ± 0.19	− 0.01 ± 0.24	0.06 ± 0.21	0.104^b
Changes in BCVA (logMAR) ^a	6 months	− 0.14 ± 0.27	0.03 ± 0.28	0.06 ± 0.29	0.011^b*	− 0.15 ± 0.26	− 0.03 ± 0.27	0.08 ± 0.29	0.002^b*
Changes in CRT (μM) ^a	3 months	− 73.9 ± 98.67	− 33.4 ± 126.33	− 15.8 ± 140.46	0.507^c	− 81.2 ± 101.09	− 36.1 ± 113.17	− 16.1 ± 143.46	0.141^c
Changes in CRT (μM) ^a	6 months	− 94.2 ± 82.17	− 49.7 ± 145.18	30.6 ± 184.27	0.022^c*	− 102.4 ± 82.16	− 52.3 ± 145.09	20.8 ± 178.85	0.003^c*

Data are presented as percentages in parentheses
CRT central retinal thickness, BCVA best-corrected visual acuity
^*Significant P value, P < 0.05
^aData presented as mean ± standard deviation (SD)
^bKruskal-Wallis test
^cMann-Whitney U test

Back to article page

ISSN: 1479-7364

Contact us

General enquiries: journalsubmissions@springernature.com